Department Metrics

• Moffitt Cancer Center Support Grant Years 24-27
  Sponsor: Nat Institutes of Health
  PI:Cleveland, J.
• Determinants of Cancer Survivorship Among People Living with HIV (HIV/AIDS/Aging Cancer)
  Sponsor: Nat Institutes of Health
  PI:Cleveland, J.,Project PI:Islam, J.
• The role of Accelerated Biological Aging in HIV control and Non-AIDS-defining Cancer Risk (Biospecimens/Biocohort)
  Sponsor: Nat Institutes of Health
  PI:Cleveland, J.,Project PI:Coghill, A.
• CCSG Developmental Project: Pilot Project for Tobacco Cessation and Machine Learning
  Sponsor: Nat Institutes of Health
  PI:Cleveland, J.,PI:Vidrine, J.
• Harnessing EHR to develop a Florida-based Coalition on Cancer Care Inequities among PHIV (Social Determinants of Health and Quality of Cancer Care in HIV-associated Cancers)
  Sponsor: Nat Institutes of Health
  PI:Cleveland, J.,Project PI:Islam, J.
• Applying Large Language Models to Accelerate Abstraction of Cancer Pathology Reports for Cancer Registry (LLMs for Unstructured Data Extraction)
  Sponsor: Nat Institutes of Health
  PI:Cleveland, J.,Project PI:Thieu, T.
• Assessing the Efficacy of Sexual Orientation and Gender Identity (SOGI) Data Collection
  Sponsor: Nat Institutes of Health
  PI:Cleveland, J.,Project PI:Schabath, M.
• Local and Systemic Control of Multiple Myeloma Colonization and Growth by MMP-13
  Sponsor: Nat Institutes of Health
  PI:Lynch, C.
• Enhancing TIL populations and immunotherapy efficacy in melanoma by modulating fucosylation
  Sponsor: Nat Institutes of Health
  PI:Le-Lau, E.
• New Therapeutic Vulnerabilities for Aggressive B-Cell Lymphoma
  Sponsor: Nat Institutes of Health
  PI:Cleveland, J.
• Defining bone ecosystem effects on metastatic prostate cancer evolution and treatment response using an integrated mathematical modeling approach
  Sponsor: Nat Institutes of Health
  PI (Contact):Lynch, C.,PI (MPI):Basanta Gutierrez, D.
• Exploiting Ecology and Evolution to Prevent Therapy Resistance in EGFR-Driven Lung Cancer
  Sponsor: Nat Institutes of Health
  PI:Marusyk, A.
• Targeted degradation of RNAs by using small molecules
  Sponsor: Nat Institutes of Health
  PI:Cleveland, J.
• CARM1-mediated regulation of YAP1 as a therapeutic target in lung cancer
  Sponsor: Nat Institutes of Health
  PI:Chellappan, S.
• Characterization and Targeting of the Epigenetic state underlying uveal melanoma liver metastasis
  Sponsor: Nat Institutes of Health
  PI (Contact):Smalley, K.
• Functional characterization of prostate cancer risk loci by high throughput sequencing
  Sponsor: Nat Institutes of Health
  PI:Wang, L.
• State of Florida Appropriation
  Sponsor: State of Florida
  PI:Cleveland, J.
• Cell free nucleic acid-based biomarkers in advanced prostate cancer
  Sponsor: Nat Institutes of Health
  PI (MPI):Wang, L.
• Defining and Targeting Epigenetic Plasticity-Driven Drug Resistance and Immune Escape in Melanoma
  Sponsor: Nat Institutes of Health
  PI (Contact):Smalley, K.
• Defining and targeting the epigenetic programs involved in melanoma development
  Sponsor: Nat Institutes of Health
  PI:Smalley, K.
• Role of ULK3 in Sensitive and Refractory Multiple Myeloma
  Sponsor: Nat Institutes of Health
  PI:Lynch, C.
• The trouble with testosterone: delineating how androgen drives melanoma invasiveness and metastasis via fucosylation-regulated cellular adhesion
  Sponsor: Florida Biomedical Research Program (FBRP)
  PI:Le-Lau, E.
• Uncovering Causal Protein Markers to Improve Prostate Cancer Etiology Understanding and Risk Prediction in Africans and Europeans
  Sponsor: Nat Institutes of Health
  PI:Wang, L.
• Novel role of melanin-carbonyls in progression of NRAS mutant melanoma
  Sponsor: Nat Institutes of Health
  PI (Contact):Premi, S.
• Modulating dendritic cell (DC) polarization and biology with L-fucose to enhance DC vaccine efficacy
  Sponsor: Florida Biomedical Research Program (FBRP)
  PI:Le-Lau, E.
• Identifying How HDAC Suppression of SLC17A7 Drives Osteosarcoma Progression and Metastasis
  Sponsor: Florida Biomedical Research Program (FBRP)
  PI:Lynch, C.
• Proprietary arginine vasopressin receptor type 1a (AVPR1a) antagonists for treatment of lethal prostate cancer
  Sponsor: US Army
  PI:Lynch, C.
• Epigenetic Changes as a Biomarker in African Americans with Papillary Renal Cell Carcinoma and a Link to the Tumor Microenvironment
  Sponsor: US Army
  PI:Wang, L.
• Role of CRTC1-MAML2 in Salivary Mucoepidermoid Carcinoma Pathobiology
  Sponsor: Nat Institutes of Health
  PI:Amelio, A.
• SOW for project management, alliance management, and Executive Sponsors in Major Alliance with Turnstone
  Sponsor: Turnstone Biologics
  PI:Cleveland, J.
• L-fucose-mediated enrichment of memory CD4+T cells and enhanced anti-melanoma immunity
  Sponsor: Nat Institutes of Health
  PI:Le-Lau, E.
• Defining the immune and signaling landscape of acral melanoma in African-American patients
  Sponsor: Moffitt Cancer Center
  PI:Smalley, K.
• Extending experimental evolutionary game theory in cancer in vivo to enable clinical translation: integrating spatio-temporal dynamics using mathematical modeling
  Sponsor: Nat Institutes of Health
  PI:Marusyk, A.
• Investigate the Mechanisms Responsible for Inhibition of CPDs by AZ and Its Analogs
  Sponsor: Sytheon, Ltd.
  PI:Premi, S.
• Optimizing immunotherapy strategies for melanoma brain metastases
  Sponsor: Florida Biomedical Research Program (FBRP)
  PI (Contact):Smalley, K.
• Proteolysis targeting chimera against nuclear receptor NR4A1 for melanoma therapy
  Sponsor: Nat Institutes of Health
  PI (MPI):Smalley, K.
• Characterization of Plant-Based Phenolic Alkanones as Next-Generation Sun Protectants for Skin Cancer Prevention
  Sponsor: US Army
  PI (Contact):Premi, S.
• Optimizing the immune mediated-destruction of NRAS mutant melanoma
  Sponsor: Melanoma Research Alliance (MRA)
  PI (Contact):Smalley, K.,PI:Jaeger, A.
• Molecular Characterization of the Salivary Adenoid Cystic Carcinoma Tumor Immune Landscape by Anatomic Subsite
  Sponsor: Adenoid Cystic Carcinoma Rsch Found (ACCRF)
  PI:Amelio, A.

CLINICAL TRIAL 17971
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Condition: Thoracic
Intervention: Not Applicable ()

CLINICAL TRIAL 19319
InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
Condition: Genitourinary
Intervention: Ifosfamide (); Not Applicable (); Radiotherapy (); Taxol (paclitaxel); cisplatin (); paclitaxel ()

CLINICAL TRIAL 19836
REPLATINUM: A Phase 3, Controlled, Open-label,Randomized Study of RRx-001 Administered Sequentially with a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer
Condition: Thoracic
Intervention: Paraplatin (carboplatin); RRx-001 (); carboplatin (); cisplatin (); etoposide ()

CLINICAL TRIAL 20003
LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer(Lung-MAP Screening Study)
Condition: Thoracic
Intervention: ALT-803 (); AMG 510 (Sotorasib); Alimta (Pemetrexed); Dexamethasone (); Folic Acid (); Gemzar (gemcitabine); IMC-1121B (Ramucirumab); Pembrolizumab (Keytruda); Pemetrexed (); Ramucirumab (); Taxotere (docetaxel); Vitamin B12 (); docetaxel (); gemcitabine ()

CLINICAL TRIAL 20386
Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC
Condition: Thoracic
Intervention: Difluoromethylornithine (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 20561
Randomized Trial of Prolonged Use of Negative Pressure Wound Therapy in Patients Undergoing Surgical Procedures for the Management of Gastrointestinal Malignancies
Condition: Gastrointestinal Tumor
Intervention:

CLINICAL TRIAL 20767
Integration of Immunotherapy into Adjuvant Therapy For Resected NSCLC: Alchemist Chemo-IO
Condition: Thoracic
Intervention: Alimta (Pemetrexed); Gemzar (gemcitabine); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); Taxol (paclitaxel); carboplatin (); cisplatin (); gemcitabine (); paclitaxel ()

CLINICAL TRIAL 21024
A Phase IIa Study of Dendritic Cell Vaccines against HER2/HER3 and Pembrolizumab in Patients with Asymptomatic Brain Metastasis from Triple Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC)
Condition: Neurologic Oncology
Intervention: DC1 Vaccine (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 20938
A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-Small Cell Lung Cancer (NSCLC) with Primary Tumors Between 1-4 cm
Condition: Thoracic
Intervention: Not Applicable (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 21158
A Phase II Study of PCSK9 Inhibitor Alirocumab and PD-1 Inhibitor Cemiplimab in Patients with Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung Cancer
Condition: Thoracic
Intervention: Alirocumab (); Cemiplimab (); REGN2810 (Cemiplimab)

CLINICAL TRIAL 21184
Thoracic Program Trial Selection Protocol
Condition: Thoracic
Intervention:

CLINICAL TRIAL 21626
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors
Condition: Thoracic
Intervention: Alimta (Pemetrexed); MK-1084 (); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); carboplatin ()

CLINICAL TRIAL 21921
A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK 2/9 Inhibitor, in Subjects with Advanced Solid Tumors and Lymphoma
Condition: Multiple
Intervention: Fadraciclib ()

CLINICAL TRIAL 22196
A First in Human Dose Escalation and Cohort Expansion Study of DLL3-directed Chimeric Antigen Receptor T-cells in Subjects with Extensive Stage Small Cell Lung Cancer
Condition: Thoracic
Intervention: LB2102 (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 22319
A Phase 1B/2 Open-Label Study to Investigate the Safety, Tolerance and Efficacy of Drug Resistant Immunotherapy with Activated, Gene Modified Allogeneic or Autologous gamma delta T Cells (DELTEX) in Combination with Maintenance Temozolomide in Subjects with Recurrent or Newly Diagnosed Glioblastoma
Condition: Neurologic Oncology
Intervention: Autologous Dendritic Cells (); Temodal (Temozolomide); Temozolomide ()

CLINICAL TRIAL 22380
A Phase II Multicenter, Open Label, Non-Randomized Study of Neoadjuvant and Adjuvant Treatment with IPH5201 and Durvalumab in Patients with Resectable, Early-Stage (II To IIIA) Non-Small Cell Lung CancEr (MATISSE)
Condition: Thoracic
Intervention: AMP-514 (Durvalumab); Alimta (Pemetrexed); Durvalumab (); MEDI4736 (Durvalumab); Paraplatin (carboplatin); Pemetrexed (); Taxol (paclitaxel); carboplatin (); cisplatin (); paclitaxel ()

CLINICAL TRIAL 22713
A Phase 1a/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination with Anticancer Therapies in Patients with Solid Malignancies
Condition: Multiple
Intervention: GS-9716 (); Sacituzumab Govitecan (); Taxotere (docetaxel); docetaxel ()

• Vincelette ND, Yu X, Kuykendall AT, Moon J, Su S, Cheng CH, Sammut R, Razabdouski TN, Nguyen HV, Eksioglu EA, Chan O, Al Ali N, Patel PC, Lee DH, Nakanishi S, Ferreira RB, Hyjek E, Mo Q, Cory S, Lawrence HR, Zhang L, Murphy DJ, Komrokji RS, Lee D, Kaufmann SH, Cleveland JL, Yun S. Trisomy 8 Defines a Distinct Subtype of Myeloproliferative Neoplasms Driven by the MYC-Alarmin Axis. Blood Cancer Discov. 2024 Jul.5(4):276-297. Pubmedid: 38713018. Pmcid: PMC11215389.
• Park R, Li J, Slebos RJC, Chaudhary R, Poole MI, Ferraris C, Farinhas J, Hernandez-Prera J, Kirtane K, Teer JK, Song X, Hall MS, Tasoulas J, Amelio AL, Chung CH. Phase Ib trial of IRX-2 plus durvalumab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Oral Oncol. 2024 Jul.154:106866. Pubmedid: 38820888.
• Marusyk A. Evolutionary gambit to defeat drug resistance in cancer. Nat Biotechnol. 2024 Jul. Pubmedid: 38965429.
• França GS, Baron M, King BR, Bossowski JP, Bjornberg A, Pour M, Rao A, Patel AS, Misirlioglu S, Barkley D, Tang KH, Dolgalev I, Liberman DA, Avital G, Kuperwaser F, Chiodin M, Levine DA, Papagiannakopoulos T, Marusyk A, Lionnet T, Yanai I. Cellular adaptation to cancer therapy along a resistance continuum. Nature. 2024 Jul.631(8022):876-883. Pubmedid: 38987605.
• Tian Y, Wu L, Huang CC, Wang L. Identify Regulatory eQTLs by Multiome Sequencing in Prostate Single Cells. bioRxiv. 2024 Jun. Pubmedid: 38948854. Pmcid: PMC11213234.
• Miti T, Desai B, Miroshnychenko D, Basanta D, Marusyk A. Dissecting the Spatially Restricted Effects of Microenvironment-Mediated Resistance on Targeted Therapy Responses. Cancers (Basel). 2024 Jun.16(13). Pubmedid: 39001467. Pmcid: PMC11240540.
• West J, Marzban S, Srivast S, Kartika S, Bravo R, Safriel R, Zarski A, Anderson A, Chung C, Amelio A. Spatial interactions modulate tumor growth and immune infiltration. Res Sq. 2024 May. Pubmedid: 38826398. Pmcid: PMC11142313.
• Janiszewska M, Tabassum DP, Castaño Z, Cristea S, Yamamoto KN, Kingston NL, Murphy KC, Shu S, Harper NW, Del Alcazar CG, Alečković M, Ekram MB, Cohen O, Kwak M, Qin Y, Laszewski T, Luoma A, Marusyk A, Wucherpfennig KW, Wagle N, Fan R, Michor F, McAllister SS, Polyak K. Author Correction: Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments. Nat Cell Biol. 2024 May.26(5):841. Pubmedid: 38443568.
• Peak T, Tian Y, Patel A, Shaw T, Obermayer A, Laborde J, Kim Y, Johnson J, Stewart P, Fang B, Teer JK, Koomen J, Berglund A, Marchion D, Francis N, Echevarria PR, Dhillon J, Clark N, Chang A, Sexton W, Zemp L, Chahoud J, Wang L, Manley B. Pathogenic Roles for RNASET2 in Clear Cell Renal Cell Carcinoma. Lab Invest. 2024 May.104(5):102041. Pubmedid: 38431116.
• Gatenby RA, Luddy KA, Teer JK, Berglund A, Freischel AR, Carr RM, Lam AE, Pienta KJ, Amend SR, Austin RH, Hammarlund EU, Cleveland JL, Tsai KY, Brown JS. Lung adenocarcinomas without driver genes converge to common adaptive strategies through diverse genetic, epigenetic, and niche construction evolutionary pathways. Med Oncol. 2024 May.41(6):135. Pubmedid: 38704802. Pmcid: PMC11070398.
• Whately KM, Sengottuvel N, Edatt L, Srivastava S, Woods AT, Tsai YS, Porrello A, Zimmerman MP, Chack AC, Jefferys SR, Yacovone G, Kim DJ, Dudley AC, Amelio AL, Pecot CV. Spon1+ inflammatory monocytes promote collagen remodeling and lung cancer metastasis through lipoprotein receptor 8 signaling. JCI Insight. 2024 May.9(9). Pubmedid: 38716730. Pmcid: PMC11141919.
• Burton C, Bitaraf A, Snyder K, Zhang C, Yoder SJ, Avram D, Du D, Yu X, Lau EK. The functional role of L-fucose on dendritic cell function and polarization. Front Immunol. 2024 Apr.15:1353570. Pubmedid: 38646527. Pmcid: PMC11026564.
• Wei GH, Dong D, Zhang P, Liu M, Wei Y, Wang Z, Xu W, Zhang Q, Zhu Y, Zhang Q, Yang X, Zhu J, Wang L. Combined SNPs sequencing and allele specific proteomics capture reveal functional causality underpinning the 2p25 prostate cancer susceptibility locus. Res Sq. 2024 Apr. Pubmedid: 38645058. Pmcid: PMC11030545.
• Carvalho LADC, Noma IHY, Uehara AH, Siena ÁDD, Osaki LH, Mori MP, Pinto NCS, Freitas VM, Junior WAS, Smalley KSM, Maria-Engler SS. Modeling Melanoma Heterogeneity In Vitro: Redox, Resistance and Pigmentation Profiles. Antioxidants (Basel). 2024 Apr.13(5). Pubmedid: 38790661. Pmcid: PMC11118096.
• Dickey BL, Putney RM, Schell MJ, Berglund AE, Amelio AL, Caudell JJ, Chung CH, Giuliano AR. Identification of a Biomarker Panel from Genome-Wide Methylation to Detect Early HPV-Associated Oropharyngeal Cancer. Cancer Prev Res (Phila). 2024 Apr.17(4):169-176. Pubmedid: 38286404. Pmcid: PMC10987272.
• Bishop RT, Miller AK, Froid M, Nerlakanti N, Li T, Frieling JS, Nasr MM, Nyman KJ, Sudalagunta PR, Canevarolo RR, Silva AS, Shain KH, Lynch CC, Basanta D. The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous drug resistant disease. Nat Commun. 2024 Mar.15(1):2458. Pubmedid: 38503736. Pmcid: PMC10951361.
• Wong J, Muralidhar R, Wang L, Huang CC. Epigenetic modifications of cfDNA in liquid biopsy for the cancer care continuum. Biomed J. 2024 Mar.100718. Pubmedid: 38522508.
• Law V, Smalley I, Evernden BR, Baldwin M, Smalley KSM, Forsyth PA. Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease. J Vis Exp. 2024 Mar.(205). Pubmedid: 38619274.
• Huelster HL, Gould B, Schiftan EA, Camperlengo L, Davaro F, Rose KM, Soupir AC, Jia S, Zheng T, Sexton WJ, Pow-Sang J, Spiess PE, Daniel Grass G, Wang L, Wang X, Vosoughi A, Necchi A, Meeks JJ, Faltas BM, Du P, Li R. Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non-organ-confined Upper Tract Urothelial Carcinoma. Eur Urol. 2024 Mar.85(3):283-292. Pubmedid: 37802683.
• Wang L, Xiao Y, Luo Y, Master RP, Mo J, Kim MC, Liu Y, Maharjan CK, Patel UM, De U, Carelock ME, Tithi TI, Li X, Shaffer DR, Guertin KR, Zhuang H, Moser E, Smalley KSM, Lv D, Zhou D, Zheng G, Zhang W. PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. J Exp Med. 2024 Mar.221(3). Pubmedid: 38334978. Pmcid: PMC10857906.
• Maranto C, Sabharwal L, Udhane V, Pitzen SP, McCluskey B, Qi S, O'Connor C, Devi S, Johnson S, Jacobsohn K, Banerjee A, Iczkowski KA, Wang L, Dehm SM, Nevalainen MT. Stat5 induces androgen receptor (AR) gene transcription in prostate cancer and offers a druggable pathway to target AR signaling. Sci Adv. 2024 Mar.10(9):eadi2742. Pubmedid: 38416822. Pmcid: PMC10901378.
• Liu Q, Adhikari E, Lester DK, Fang B, Johnson JO, Tian Y, Mockabee-Macias AT, Izumi V, Guzman KM, White MG, Koomen JM, Wargo JA, Messina JL, Qi J, Lau EK. Androgen drives melanoma invasiveness and metastatic spread by inducing tumorigenic fucosylation. Nat Commun. 2024 Feb.15(1):1148. Pubmedid: 38326303. Pmcid: PMC10850104.
• Marzban S, Srivastava S, Kartika S, Bravo R, Safriel R, Zarski A, Anderson A, Chung CH, Amelio AL, West J. Spatial interactions modulate tumor growth and immune infiltration. bioRxiv. 2024 Mar. Pubmedid: 38370722. Pmcid: PMC10871273.
• Smalley I, Boire A, Brastianos P, Kluger HM, Hernando-Monge E, Forsyth PA, Ahmed KA, Smalley KSM, Ferguson S, Davies MA, Glitza Oliva IC. Leptomeningeal disease in melanoma: An update on the developments in pathophysiology and clinical care. Pigment Cell Melanoma Res. 2024 Jan.37(1):51-67. Pubmedid: 37622466.
• Tasoulas J, Farquhar DR, Sheth S, Hackman T, Yarbrough WG, Agala CB, Koric A, Giraldi L, Fabianova E, Lissowska J, Świątkowska B, Vilensky M, Wünsch-Filho V, de Carvalho MB, López RVM, Holcátová I, Serraino D, Polesel J, Canova C, Richiardi L, Zevallos JP, Ness A, Pring M, Thomas SJ, Dudding T, Lee YA, Hashibe M, Boffetta P, Olshan AF, Divaris K, Amelio AL. Poor oral health influences head and neck cancer patient survival: an International Head and Neck Cancer Epidemiology Consortium pooled analysis. J Natl Cancer Inst. 2024 Jan.116(1):105-114. Pubmedid: 37725515. Pmcid: PMC10777670.
• Eroglu Z, Chen YA, Smalley I, Li J, Markowitz JK, Brohl AS, Tetteh L, Taylor H, Sondak VK, Khushalani NI, Smalley KSM. Combined BRAF, MEK, and heat-shock protein 90 inhibition in advanced BRAF V600-mutant melanoma. Cancer. 2024 Jan.130(2):232-243. Pubmedid: 37776537.
• Yun S, Cleveland JL. Transcriptional Plasticity Drives IMiD and p300 Inhibitor Resistance in Multiple Myeloma. Blood Cancer Discov. 2024 Jan.5(1):5-7. Pubmedid: 38085608. Pmcid: PMC10772544.
• Jinesh GG, Smallin MT, Mtchedlidze N, Godwin I, Napoli M, Hackel N, Phadke MS, Deshpande AA, Li X, Lockhart JH, Baldwin JR, Acevedo-Acevedo S, Gao Y, Reiser MA, Smalley KSM, Flores ER, Brohl AS. C19MC miRNA-520G induces SP100 antiviral gene transcription and inhibits melanin production in skin cutaneous melanoma. Genes Dis. 2024 Jan.11(1):60-63. Pubmedid: 37588194. Pmcid: PMC10425800.
• Carvalho LAD, Aguiar FC, Smalley KSM, Possik PA. Acral melanoma: new insights into the immune and genomic landscape. Neoplasia. 2023 Dec.46:100947. Pubmedid: 37913653. Pmcid: PMC10637990.
• Burger KL, Fernandez MR, Meads MB, Sudalagunta PR, Oliveira PS, Renatino Canevarolo R, Alugubelli RR, Tungsevik A, De Avila G, Silva M, Graeter AI, Dai H, Vincelette ND, Prabhu A, Magaletti D, Yang C, Li W, Kulkarni A, Hampton OA, Koomen JM, Roush WR, Monastyrskyi A, Berglund AE, Silva AS, Cleveland JL, Shain KH. CK1δ and CK1ε Signaling Sustains Mitochondrial Metabolism and Cell Survival in Multiple Myeloma. Cancer Res. 2023 Dec.83(23):3901-3919. Pubmedid: 37702657. Pmcid: PMC10690099.
• Nasr MM, Lynch CC. How circulating tumor cluster biology contributes to the metastatic cascade: from invasion to dissemination and dormancy. Cancer Metastasis Rev. 2023 Dec.42(4):1133-1146. Pubmedid: 37442876. Pmcid: PMC10713810.
• Adhikari E, Liu Q, Johnson J, Stewart P, Marusyk V, Fang B, Izumi V, Bowers K, Guzman KM, Koomen JM, Marusyk A, Lau EK. Brain metastasis-associated fibroblasts secrete fucosylated PVR/CD155 that induces breast cancer invasion. Cell Rep. 2023 Dec.42(12):113463. Pubmedid: 37995180.
• Phadke MS, Li J, Chen Z, Rodriguez PC, Mandula JK, Karapetyan L, Forsyth PA, Chen YA, Smalley KSM. Differential requirements for CD4+ T cells in the efficacy of the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain metastasis models. J Immunother Cancer. 2023 Dec.11(12). Pubmedid: 38056899. Pmcid: PMC10711842.
• Arteaga CL, Cleveland JL, Foti M, Mesa RA, Weiner LM, Willman CL, Tuveson DA. AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients. Cancer Discov. 2023 Nov.13(11):2316-2318. Pubmedid: 37702762.
• Emmons MF, Bennett RL, Riva A, Gupta K, Carvalho LADC, Zhang C, Macaulay R, Dupéré-Richér D, Fang B, Seto E, Koomen JM, Li J, Chen YA, Forsyth PA, Licht JD, Smalley KSM. HDAC8-mediated inhibition of EP300 drives a transcriptional state that increases melanoma brain metastasis. Nat Commun. 2023 Nov.14(1):7759. Pubmedid: 38030596. Pmcid: PMC10686983.
• Lau EK. Research does not happen in a socio-political vacuum - we should not pretend that it does. Nat Rev Cancer. 2023 Nov.23(11):725-726. Pubmedid: 37723271.
• Arteaga CL, Cleveland JL, Foti M, Mesa RA, Weiner LM, Willman CL, Tuveson DA. AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients. Cancer Res. 2023 Nov.83(21):3504-3506. Pubmedid: 37732910.
• Arteaga CL, Cleveland JL, Foti M, Mesa RA, Weiner LM, Willman CL, Tuveson DA. AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients. Mol Cancer Ther. 2023 Nov.22(11):1245-1247. Pubmedid: 37732909.
• Arteaga CL, Cleveland JL, Foti M, Mesa RA, Weiner LM, Willman CL, Tuveson DA. AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients. Blood Cancer Discov. 2023 Nov.4(6):420-422. Pubmedid: 37732908. Pmcid: PMC10621678.
• Arteaga CL, Cleveland JL, Foti M, Mesa RA, Weiner LM, Willman CL, Tuveson DA. AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients. Clin Cancer Res. 2023 Nov.29(21):4338-4340. Pubmedid: 37732904.
• Arteaga CL, Cleveland JL, Foti M, Mesa RA, Weiner LM, Willman CL, Tuveson DA. AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients. Cancer Prev Res (Phila). 2023 Nov.16(11):591-594. Pubmedid: 37732897.
• Arteaga CL, Cleveland JL, Foti M, Mesa RA, Weiner LM, Willman CL, Tuveson DA. AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients. Cancer Immunol Res. 2023 Nov.11(11):1446-1448. Pubmedid: 37732896.
• Arteaga CL, Cleveland JL, Foti M, Mesa RA, Weiner LM, Willman CL, Tuveson DA. AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients. Mol Cancer Res. 2023 Nov.21(11):1139-1141. Pubmedid: 37732893.
• Arteaga CL, Cleveland JL, Foti M, Mesa RA, Weiner LM, Willman CL, Tuveson DA. AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients. Cancer Epidemiol Biomarkers Prev. 2023 Nov.32(11):1482-1484. Pubmedid: 37732892.
• Miroshnychenko D, Miti T, Kumar P, Miller A, Laurie M, Giraldo N, Bui MM, Altrock PM, Basanta D, Marusyk A. Stroma-Mediated Breast Cancer Cell Proliferation Indirectly Drives Chemoresistance by Accelerating Tumor Recovery between Chemotherapy Cycles. Cancer Res. 2023 Nov.83(22):3681-3692. Pubmedid: 37791818. Pmcid: PMC10646478.
• Li Q, Huang CC, Huang S, Tian Y, Huang J, Bitaraf A, Dong X, Nevalanen MT, Zhang J, Manley BJ, Park JY, Kohli M, Gore EM, Kilari D, Wang L. 5-hydroxymethylcytosine sequencing in plasma cell-free DNA identifies unique epigenomic features in prostate cancer patients resistant to androgen deprivation therapy. medRxiv. 2023 Oct. Pubmedid: 37904926. Pmcid: PMC10615016.
• Sasamoto N, Stewart PA, Wang T, Thompson ZJ, Yoder SJ, Hecht JL, Cleveland JL, Conejo-Garcia J, Fridley BL, Terry KL, Tworoger SS. Associations between prediagnostic aspirin use and ovarian tumor gene expression. Cancer Med. 2023 Sep.12(17):18405-18417. Pubmedid: 37525619. Pmcid: PMC10523980.
• Elmarsafawi AG, Hesterberg RS, Fernandez MR, Yang C, Darville LN, Liu M, Koomen JM, Phanstiel Iv O, Atkins R, Mullinax JE, Pilon-Thomas SA, Locke FL, Epling-Burnette PK, Cleveland JL. Modulating the polyamine/hypusine axis controls generation of CD8+ tissue-resident memory T cells. JCI Insight. 2023 Sep.8(18). Pubmedid: 37581943. Pmcid: PMC10561731.
• Velayutham S, Seerattan R, Sultan M, Seal T, Danthurthy S, Chinnappan B, Landi J, Pearl K, Singh A, Smalley KSM, Zaias J, Choi JY, Minond D. Novel Anti-Melanoma Compounds Are Efficacious in A375 Cell Line Xenograft Melanoma Model in Nude Mice. Biomolecules. 2023 Aug.13(9). Pubmedid: 37759675. Pmcid: PMC10526148.
• Tian Y, Dong D, Wang Z, Wu L, Park JY, Wei GH, Wang L. Combined CRISPRi and proteomics screening reveal a cohesin-CTCF-bound allele contributing to increased expression of RUVBL1 and prostate cancer progression. Am J Hum Genet. 2023 Aug.110(8):1289-1303. Pubmedid: 37541187. Pmcid: PMC10432188.
• Tasoulas J, Srivastava S, Xu X, Tarasova V, Maniakas A, Karreth FA, Amelio AL. Genetically engineered mouse models of head and neck cancers. Oncogene. 2023 Aug.42(35):2593-2609. Pubmedid: 37474617. Pmcid: PMC10457205.
• Rose KM, Huelster HL, Meeks JJ, Faltas BM, Sonpavde GP, Lerner SP, Ross JS, Spiess PE, Grass GD, Jain RK, Kamat AM, Vosoughi A, Wang L, Wang X, Li R. Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease. Nat Rev Urol. 2023 Jul.20(7):406-419. Pubmedid: 36977797.
• Capp JP, Thomas F, Marusyk A, M Dujon A, Tissot S, Gatenby R, Roche B, Ujvari B, DeGregori J, Brown JS, Nedelcu AM. The paradox of cooperation among selfish cancer cells. Evol Appl. 2023 Jul.16(7):1239-1256. Pubmedid: 37492150. Pmcid: PMC10363833.
• Gatenbee CD, Baker AM, Prabhakaran S, Swinyard O, Slebos RJC, Mandal G, Mulholland E, Andor N, Marusyk A, Leedham S, Conejo-Garcia JR, Chung CH, Robertson-Tessi M, Graham TA, Anderson ARA. Virtual alignment of pathology image series for multi-gigapixel whole slide images. Nat Commun. 2023 Jul.14(1):4502. Pubmedid: 37495577. Pmcid: PMC10372014.
• Nakanishi S, Li J, Berglund AE, Kim Y, Zhang Y, Zhang L, Yang C, Song J, Mirmira RG, Cleveland JL. The Polyamine-Hypusine Circuit Controls an Oncogenic Translational Program Essential for Malignant Conversion in MYC-Driven Lymphoma. Blood Cancer Discov. 2023 Jul.4(4):294-317. Pubmedid: 37070973. Pmcid: PMC10320645.
• Rose KM, Huelster HL, Meeks JJ, Faltas BM, Sonpavde GP, Lerner SP, Ross JS, Spiess PE, Grass GD, Jain RK, Kamat AM, Vosoughi A, Wang L, Wang X, Li R. Author Correction: Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease. Nat Rev Urol. 2023 Jul.20(7):452. Pubmedid: 37217696.